Mavacamten is approved, but neither target nor Mechanisms of Action cannot be identified by OpenTargets. Any optimization can be done?
4 days ago — Camzyos™ ( mavacamten ) is the first and only cardiac myosin inhibitor approved by the U.S. Food and Drug Administration (FDA) indicated for the …
Here is the Mevacamten page from the Open Targets platform. Our mechanism of action data is taken from ChEMBL. Once they have include further information it will flow through to the platform.